Search

Displaying results 2141 - 2150 of 7479 in total
  1. Drug

    Trospium

    go.drugbank.com/drugs/DB00209
    ApprovedInvestigational

    [L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. … Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.

  2. Drug

    Ceftobiprole medocaril

    go.drugbank.com/drugs/DB14733
    Approved

    Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due

  3. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: SLITone ULTRA D. glomerata/ L. perenne/ P. pratense/ P. pratensis/ A. odoratum
  4. Drug

    Anthoxanthum odoratum pollen

    go.drugbank.com/drugs/DB10404
    Approved

    Anthoxanthum odoratum pollen is the pollen of the Anthoxanthum odoratum plant. Anthoxanthum odoratum pollen is mainly used in allergenic testing.

    Mixtures: SLITone ULTRA D. glomerata/ L. perenne/ P. pratense/ P. pratensis/ A. odoratum
  5. Drug

    Mangafodipir

    go.drugbank.com/drugs/DB06796
    ApprovedInvestigationalWithdrawn

    Mangafodipir is a contrast agent used as a diagnostic tool administered intravenously to enhance contrast in magnetic resonance imaging (MRI) of the liver and pancreas. This drug is made up of paramagnetic manganese (II) ions combined wi...

  6. Drug

    Tribromsalan

    go.drugbank.com/drugs/DB20138
    ApprovedWithdrawn

    Tribromsalan has a monoisotopic molecular weight of 446.81 Da.

  7. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment

  8. Drug

    Zenocutuzumab

    go.drugbank.com/drugs/DB15559
    ApprovedInvestigational

    [L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher. … [L51963] It works to attenuate aberrant cancer cell growth caused by genomic rearrangements involving the neuregulin 1 gene (NRG1), which is an oncogenic driver.

  9. Drug

    Bunamiodyl

    go.drugbank.com/drugs/DB04814
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.

  10. Drug

    Dantron

    go.drugbank.com/drugs/DB04816
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1998 due to genotoxicity.

    Mixtures: Regulex D CapInternational brands: Scatron D